Bayer expands collaboration with Broad Institute to cardiovascular genomics

German drug major Bayer (BAYN: DE) has extended its collaboration with the USA's Broad Institute of MIT and Harvard to include cardiovascular genomics and drug discovery.

This new aspect of the collaboration aims to use insights from human genetics to create new cardiovascular therapies.

Andreas Busch, head of global drug discovery at Bayer HealthCare, said: “We are excited to broaden our collaboration with the Broad Institute to the area of cardiovascular genomics to discover genes and mutational changes underlying cardiovascular disorders in order to develop new therapies and diagnostic options for these diseases. We have been collaborating already for the last two years and have developed a very constructive partnership during this time.”